VIDEO: COVID adds difficulty in interpreting results of randomized trials

ByDavid Statman

In this video, Jakub Svoboda, MD, discusses the results of the phase 3 Alliance study, pertaining to chronic lymphocytic leukemia, presented at ASCO Annual Meeting.

Svoboda, an associate professor of medicine at Hospital of the University of Pennsylvania, highlighted the study, which examined the impact of adding venetoclax (Venclexta; Genentech, AbbVie) to the standard combination therapy of ibrutinib (Imbruvica; Pharmacyclics, Janssen) and obinutuzumab (Gazyva, Genentech) in older patients with CLL. Svoboda also pondered the effect COVID-19 had on health outcomes in randomized trials.

“You invest so much effort, so much money, so many resources into these randomized trials where you have 400-plus patients, and then this pandemic rolls in, and it can change the outcomes and these results,” Svoboda said.

Reference:

Woyach J, et al. Abstract 7500. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.

Published by:

Sources/Disclosures

Collapse

Source:

Disclosures: Svoboda reports no relevant financial disclosures.

Take Homes in Leukemia

Read more

VIDEO: COVID adds difficulty in interpreting results of randomized trials

Reference:

Related Content